Outbreak of methanol-induced optic neuropathy in early COVID-19 era; effectiveness of erythropoietin and methylprednisolone therapy.
Alcohol
COVID-19
Erythropoietin
Ethanol
Methanol
Optic neuropathy
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
26 May 2023
26 May 2023
Historique:
received:
07
01
2023
revised:
01
02
2023
accepted:
14
04
2023
medline:
29
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Methanol is a highly toxic, non-potable alcohol. Outbreaks of methanol toxicity occur due to its fraudulent addition to alcoholic beverages as a cheaper substitute for ethanol. Recently, alongside the coronavirus disease 2019 (COVID-19) pandemic, rumors circulated on social media that consuming alcohol can prevent or cure the virus, leading to a COVID-19 and methanol-induced optic neuropathy (MON) syndemic. To investigate the impact of erythropoietin (EPO) on the outcomes of patients diagnosed with MON. In this prospective study, 105 patients presenting with acute bilateral visual loss secondary to methanol intoxication were enrolled from March to May 2020 at Farabi Eye Hospital. A comprehensive ocular examination was conducted for all participants. Recombinant human EPO and methylprednisolone were administered intravenously to all patients for three consecutive days. The mean age of the participants was 39.9 years (± 12.6). Ninety-four patients were male and eleven were female. The mean pre-treatment best corrected visual acuity (BCVA) improved from 2.0 ± 0.86 to 1.39 ± 0.69 logarithm of the minimum angle of resolution post-treatment ( EPO and methylprednisolone therapy have been shown to be effective in improving visual outcomes in patients with MON when administrated within the first month of exposure. Public awareness efforts are necessary to prevent further outbreaks of methanol toxicity in the current COVID-19 era.
Sections du résumé
BACKGROUND
BACKGROUND
Methanol is a highly toxic, non-potable alcohol. Outbreaks of methanol toxicity occur due to its fraudulent addition to alcoholic beverages as a cheaper substitute for ethanol. Recently, alongside the coronavirus disease 2019 (COVID-19) pandemic, rumors circulated on social media that consuming alcohol can prevent or cure the virus, leading to a COVID-19 and methanol-induced optic neuropathy (MON) syndemic.
AIM
OBJECTIVE
To investigate the impact of erythropoietin (EPO) on the outcomes of patients diagnosed with MON.
METHODS
METHODS
In this prospective study, 105 patients presenting with acute bilateral visual loss secondary to methanol intoxication were enrolled from March to May 2020 at Farabi Eye Hospital. A comprehensive ocular examination was conducted for all participants. Recombinant human EPO and methylprednisolone were administered intravenously to all patients for three consecutive days.
RESULTS
RESULTS
The mean age of the participants was 39.9 years (± 12.6). Ninety-four patients were male and eleven were female. The mean pre-treatment best corrected visual acuity (BCVA) improved from 2.0 ± 0.86 to 1.39 ± 0.69 logarithm of the minimum angle of resolution post-treatment (
CONCLUSION
CONCLUSIONS
EPO and methylprednisolone therapy have been shown to be effective in improving visual outcomes in patients with MON when administrated within the first month of exposure. Public awareness efforts are necessary to prevent further outbreaks of methanol toxicity in the current COVID-19 era.
Identifiants
pubmed: 37383889
doi: 10.12998/wjcc.v11.i15.3502
pmc: PMC10294205
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3502-3510Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Références
Neural Regen Res. 2012 Feb 5;7(4):295-301
pubmed: 25806072
Alcohol. 2020 Nov;88:29-32
pubmed: 32693023
J Glaucoma. 2015 Mar;24(3):214-8
pubmed: 23835669
Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):18-25
pubmed: 20128565
Clin Toxicol (Phila). 2011 Feb;49(2):102-7
pubmed: 21370946
N Engl J Med. 2001 Feb 8;344(6):424-9
pubmed: 11172179
Med Toxicol. 1986 Sep-Oct;1(5):309-34
pubmed: 3537623
Aust N Z J Ophthalmol. 1997 Aug;25(3):225-30
pubmed: 9296298
PLoS One. 2016 Mar 31;11(3):e0152676
pubmed: 27030969
J Neurosci. 2001 Dec 15;21(24):9733-43
pubmed: 11739582
Neurosciences (Riyadh). 2012 Apr;17(2):151-5
pubmed: 22465890
Cutan Ocul Toxicol. 2018 Jun;37(2):186-190
pubmed: 28849680
Am J Drug Alcohol Abuse. 2016 Nov;42(6):633-639
pubmed: 27463192
Brain Res. 2005 Jul 19;1050(1-2):15-26
pubmed: 15979589
Alcohol Alcohol. 2019 Mar 1;54(2):128-130
pubmed: 30715164
Cutan Ocul Toxicol. 2020 Sep;39(3):173-179
pubmed: 32396759
Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):731-6
pubmed: 20890611
Crit Care. 2020 Jul 9;24(1):402
pubmed: 32646475
J Public Health (Oxf). 2015 Jun;37(2):354-9
pubmed: 24944254
Pathobiology. 2011;78(1):41-53
pubmed: 21474975
BMC Res Notes. 2013 Nov 20;6:479
pubmed: 24256873
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1236-40
pubmed: 16505064
Acta Med Scand. 1983;213(2):105-10
pubmed: 6837328
Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):2043-2048
pubmed: 27510295
Pharmacol Toxicol. 1991 Sep;69(3):157-63
pubmed: 1665561
Indian J Ophthalmol. 2006 Mar;54(1):68-9
pubmed: 16531683
World J Clin Cases. 2022 Jul 6;10(19):6571-6579
pubmed: 35979299
J Neuroophthalmol. 2012 Dec;32(4):325-8
pubmed: 22810212
J Ocul Pharmacol Ther. 2011 Jun;27(3):261-3
pubmed: 21663445
J Neuroophthalmol. 2018 Jun;38(2):167-171
pubmed: 29300238
J Toxicol Clin Toxicol. 2002;40(4):415-46
pubmed: 12216995
Graefes Arch Clin Exp Ophthalmol. 2021 May;259(5):1375-1376
pubmed: 32910310
Br J Ophthalmol. 2011 Jul;95(7):992-5
pubmed: 21131378
World J Crit Care Med. 2020 Aug 7;9(3):54-62
pubmed: 32844091
Jpn J Ophthalmol. 2006 May-Jun;50(3):239-41
pubmed: 16767379
Expert Rev Clin Pharmacol. 2016 Jul;9(7):981-9
pubmed: 26966785
Neuroradiology. 2007 May;49(5):427-35
pubmed: 17294234
Ann Neurol. 2012 Aug;72(2):199-210
pubmed: 22926853